Protection against Streptococcus pneumoniae elicited by immunization with pneumolysin and CbpA

Infection and Immunity
Abiodun D OgunniyiJames C Paton

Abstract

The need for the development of cheap and effective vaccines against pneumococcal disease has necessitated the evaluation of common virulence-associated proteins of Streptococcus pneumoniae as potential vaccine antigens. In this study, we examined the capacity of active immunization with a genetic toxoid derivative of pneumolysin (PdB) and/or a fragment of choline binding protein A (CbpA; also known as PspC, Hic, and SpsA) to protect mice from intraperitoneal challenge with medium to very high doses of a highly virulent capsular type 2 pneumococcal strain, D39. The median survival times for mice immunized with the individual protein antigens in different adjuvant combinations were significantly longer than those for mice that received the respective adjuvants alone. Mice immunized with CbpA alone were significantly better protected than mice immunized with PdB alone. Correspondingly, the median survival times for mice that were immunized with a combination of PdB and CbpA were significantly longer than those for mice that received PdB alone but not significantly different from those that received CbpA alone. Mice immunized with the protein antigens in a mixture of monophospholipid A (MPL) and aluminium phosphate (AlPO4) adjuvan...Continue Reading

References

Feb 1, 1987·The Journal of Experimental Medicine·Larry S McDanielDavid E Briles
Nov 1, 1984·Infection and Immunity·A FerranteJames C Paton
Mar 1, 1984·Infection and Immunity·James C PatonA Ferrante
May 16, 1998·Trends in Microbiology·James C Paton
Apr 27, 2000·The Pediatric Infectious Disease Journal·J Eskola
Jul 29, 2000·The Journal of Infectious Diseases·B L Smith, M K Hostetter
Sep 1, 2000·The Journal of Biological Chemistry·R JanulczykLars Björck
Apr 9, 2001·Infection and Immunity·S DaveLarry S McDaniel

Citations

Mar 21, 2007·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·J M Garcia-LechuzSpanish Pneumococcal Study Network
May 20, 2004·Vaccine·D BogaertR de Groot
Jul 28, 2011·The Journal of Infectious Diseases·Oluwadamilola H IwajomoRobert S Heyderman
Jul 24, 2004·Infection and Immunity·María del Mar García-SuárezFrancisco J Méndez
Jan 25, 2005·Infection and Immunity·Ravichandran PalaniappanJames W Lillard
Jan 16, 2007·Journal of Bacteriology·Zhuo Ma, Jing-Ren Zhang
Jan 5, 2006·Journal of Clinical Microbiology·Lea-Ann S KirkhamT Mitchell
Jan 30, 2007·Respiratory Research·María del Mar García-SuárezFrancisco J Méndez
Oct 14, 2014·Vaccines·Shifeng Wang, Roy Curtiss
Dec 28, 2012·Cellular and Molecular Life Sciences : CMLS·E N MiyajiPaulo L Ho
Jul 31, 2013·Critical Reviews in Microbiology·M DarrieuxLuciana Cezar de Cerqueira Leite
Apr 23, 2002·Pediatric Annals·Barry M Gray
Sep 22, 2015·International Journal of Pharmaceutics·Nitesh K KundaImran Y Saleem
Nov 4, 2006·Vaccine·Sandrine A L AudouyPeter W M Hermans
Sep 22, 2006·Enfermedades infecciosas y microbiología clínica·María del Mar García-SuárezFrancisco J Méndez
Feb 11, 2015·Human Vaccines & Immunotherapeutics·M Nadeem Khan, Michael E Pichichero
Dec 3, 2014·Applied Biochemistry and Biotechnology·Ana Paula Corrêa ArgondizzoMarco Alberto Medeiros
Oct 6, 2006·FEMS Microbiology Letters·Lisa R QuinLarry S McDaniel
Nov 24, 2007·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·C MorsczeckP Schrotz-King
Sep 23, 2016·Expert Review of Vaccines·Susanna Esposito, Nicola Principi
Oct 16, 2004·Expert Review of Vaccines·Jan Poolman
Dec 30, 2016·Clinical and Vaccine Immunology : CVI·Lea-Ann S KirkhamRuth B Thornton
May 9, 2014·Clinical and Vaccine Immunology : CVI·Cintia F M VadesilhoE N Miyaji
Oct 17, 2018·Clinical and Experimental Immunology·E OliverAdam Finn
Oct 31, 2008·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Abiodun D OgunniyiJames C Paton
May 17, 2002·Current Opinion in Infectious Diseases·Riana CockeranCharles Feldman
Jul 24, 2017·Archives of Pharmacal Research·Gyu-Lee KimDong-Kwon Rhee
Oct 14, 2017·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·D C AndradeC M Nascimento-Carvalho
Nov 5, 2008·The Journal of Immunology : Official Journal of the American Association of Immunologists·Ling LuJing-Ren Zhang
Jan 13, 2019·Journal of Biomolecular Structure & Dynamics·Hesam DorostiYounes Ghasemi
Jul 28, 2020·Frontiers in Microbiology·Andrew T NishimotoElaine I Tuomanen

Related Concepts

PlY protein, Streptococcus pneumoniae
SpsA protein, Streptococcus pneumoniae
Antibodies, Bacterial
Antigens, Bacterial
Bacterial Proteins
Histidine
Mice, Inbred BALB C
Pneumococcal Infections
Chimeric Proteins, Recombinant
Streptolysins

Related Feeds

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.